Claudine Lapoumeroulie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Claudine Lapoumeroulie has a total of 349 co-authors. Here are the top co-authors by number of shared publications:
- Jacques Elion
Laboratoire d’Excellence GR-Ex, UMR_S1134, Inserm, Université Paris Diderot, Sorbonne Paris Cité, Institut National de la Transfusion Sanguine, 75015 Paris, France
29 shared publications Rajagopal Krishnamoorthy
13 shared publicationsDominique Labie
ICGM CHU Cochin Port-Royal, Paris, France
10 shared publicationsD. Labie
ICGM CHU Cochin Port-Royal, Paris, France
7 shared publications- Rajagopal Krishnamoorthy
INSERM, U1160, Hôpital Saint Louis, 75010, Paris, France
6 shared publications - Caroline Le Van Kim
Université Paris Cité and Université des Antilles, Inserm, BIGR Paris France
5 shared publications
Latest Publications
- 29 November 2020
- Published by Wiley in British Journal of Haematology
- Vol. 192 (3) , 634-642
Cell‐derived microparticles and sickle cell disease chronic vasculopathy in sub‐Saharan Africa: A multinational study
Although most individuals with sickle cell disease (SCD) live in sub‐Saharan Africa, the natural history of the disease on this continent remains largely unknown. Intravascular haemolysis results in activation of circulating blood cells and release of microparticles (MPs) that exert pro‐inflammatory effects and contribute to vascular damage. We designed a case‐control study nested in the CADRE cohort (Coeur‐Artère‐DRÉpanocytose, clinical trials.gov identifier NCTO3114137) and based on extreme phenotypes, to analyse blood cell‐derived MPs in 232 adult SS patients at steady state in Bamako and Dakar. Thirty‐six healthy adult controls matched by age and sex were recruited in Bamako. The MPs concentrations were higher in SS patients compared to AA controls with a predominance of erythrocyte‐ and reticulocyte‐derived MPs. These erythroid‐derived MPs were significantly lower in patients with retinopathy (P = 0·022). Reticulocyte‐derived MPs were significantly negatively and positively associated with a history of priapism (P = 0·020) and leg ulcers (P = 0·041) respectively. We describe for the first time the comparative patterns of plasma MPs in healthy subjects and patients with SCD living in sub‐Saharan Africa and exhibiting various complications. Because our present results show no clear pattern of correlation between erythroid MPs and the classical hyper‐haemolytic complications, we hypothesise a weak relevance of the hyper‐haemolysis versus hyper‐viscous paradigm in Africa.
- 29 November 2020
- Published by Wiley in British Journal of Haematology
- Vol. 192 (3) , 634-642
Cell‐derived microparticles and sickle cell disease chronic vasculopathy in sub‐Saharan Africa: A multinational study
Although most individuals with sickle cell disease (SCD) live in sub‐Saharan Africa, the natural history of the disease on this continent remains largely unknown. Intravascular haemolysis results in activation of circulating blood cells and release of microparticles (MPs) that exert pro‐inflammatory effects and contribute to vascular damage. We designed a case‐control study nested in the CADRE cohort (Coeur‐Artère‐DRÉpanocytose, clinical trials.gov identifier NCTO3114137) and based on extreme phenotypes, to analyse blood cell‐derived MPs in 232 adult SS patients at steady state in Bamako and Dakar. Thirty‐six healthy adult controls matched by age and sex were recruited in Bamako. The MPs concentrations were higher in SS patients compared to AA controls with a predominance of erythrocyte‐ and reticulocyte‐derived MPs. These erythroid‐derived MPs were significantly lower in patients with retinopathy (P = 0·022). Reticulocyte‐derived MPs were significantly negatively and positively associated with a history of priapism (P = 0·020) and leg ulcers (P = 0·041) respectively. We describe for the first time the comparative patterns of plasma MPs in healthy subjects and patients with SCD living in sub‐Saharan Africa and exhibiting various complications. Because our present results show no clear pattern of correlation between erythroid MPs and the classical hyper‐haemolytic complications, we hypothesise a weak relevance of the hyper‐haemolysis versus hyper‐viscous paradigm in Africa.
- 9 July 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (2) , 247-256
Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties
Microparticles (MPs) are submicron extracellular vesicles exposing phosphatidylserine (PS) detected in large quantities in the circulation of sickle cell anemia (SS) patients. Several groups studied the biological effects of MPs generated ex vivo. Here, we analyzed for the first time the impact of circulating MPs of 60 sickle cell disease (SCD) patients on endothelial cells (ECs). (1) SCD MPs were collected cross-sectionally, and compared to MPs isolated from healthy individuals (AA); whereas other plasma MPs were purified in a longitudinal manner, from SS patients (2) before and 2 years after hydroxyurea (HU) treatment onset, or (3) during a vaso-occlusive crisis and at steady state. SS MPs increased EC ICAM-1 mRNA and protein levels, as well as neutrophil adhesion, compared to AA MPs. We showed that ICAM-1 overexpression was mainly caused by MPs derived from erythrocytes, rather than from platelets, and that it was abolished by MPs PS capping using annexin V. MPs from SS patients treated with HU were less potent to induce a pro-inflammatory phenotype in ECs, compared to MPs collected before therapy. In contrast, MPs released during crisis increased ICAM-1 and neutrophil adhesion levels, in a PS-dependent manner, compared to MPs collected at steady state. Furthermore, neutrophil adhesion was abolished by a blocking anti-ICAM-1 antibody. Our study provides evidence that MPs play a key role in SCD pathophysiology by triggering a pro-inflammatory phenotype of endothelial cells. We also uncover a new mode of action for HU and identify potential therapeutics, namely annexin V and anti-ICAM-1 antibodies.
- 9 July 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (2) , 247-256
Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties
Microparticles (MPs) are submicron extracellular vesicles exposing phosphatidylserine (PS) detected in large quantities in the circulation of sickle cell anemia (SS) patients. Several groups studied the biological effects of MPs generated ex vivo. Here, we analyzed for the first time the impact of circulating MPs of 60 sickle cell disease (SCD) patients on endothelial cells (ECs). (1) SCD MPs were collected cross-sectionally, and compared to MPs isolated from healthy individuals (AA); whereas other plasma MPs were purified in a longitudinal manner, from SS patients (2) before and 2 years after hydroxyurea (HU) treatment onset, or (3) during a vaso-occlusive crisis and at steady state. SS MPs increased EC ICAM-1 mRNA and protein levels, as well as neutrophil adhesion, compared to AA MPs. We showed that ICAM-1 overexpression was mainly caused by MPs derived from erythrocytes, rather than from platelets, and that it was abolished by MPs PS capping using annexin V. MPs from SS patients treated with HU were less potent to induce a pro-inflammatory phenotype in ECs, compared to MPs collected before therapy. In contrast, MPs released during crisis increased ICAM-1 and neutrophil adhesion levels, in a PS-dependent manner, compared to MPs collected at steady state. Furthermore, neutrophil adhesion was abolished by a blocking anti-ICAM-1 antibody. Our study provides evidence that MPs play a key role in SCD pathophysiology by triggering a pro-inflammatory phenotype of endothelial cells. We also uncover a new mode of action for HU and identify potential therapeutics, namely annexin V and anti-ICAM-1 antibodies.
- Open Access
- 22 November 2018
- Published by Wiley in British Journal of Haematology
- Vol. 185 (5) , 991-994
New insights into red cell rheology and adhesion in patients with sickle cell anaemia during vaso‐occlusive crises
- 22 November 2018
- Published by Wiley in British Journal of Haematology
- Vol. 185 (5) , 991-994
Open AccessNew insights into red cell rheology and adhesion in patients with sickle cell anaemia during vaso‐occlusive crises
- Open Access
- 18 October 2018
- Published by Wiley in British Journal of Haematology
- Vol. 183 (4) , 648-660
Newborn screening for sickle cell disease in Europe: recommendations from a Pan‐European Consensus Conference
Summary: Sickle Cell Disease (SCD) is an increasing global health problem and presents significant challenges to European health care systems. Newborn screening (NBS) forSCDenables early initiation of preventive measures and has contributed to a reduction in childhood mortality fromSCD. Policies and methodologies forNBSvary in different countries, and this might have consequences for the quality of care and clinical outcomes forSCDacross Europe. A two‐day Pan‐European consensus conference was held in Berlin in April 2017 in order to appraise the current status ofNBSforSCDand to develop consensus‐based statements on indications and methodology forNBSforSCDin Europe. More than 50SCDexperts from 13 European countries participated in the conference. This paper aims to summarise the discussions and present consensus recommendations which can be used to support the development ofNBSprogrammes in European countries where they do not yet exist, and to review existing programmes.
- 18 October 2018
- Published by Wiley in British Journal of Haematology
- Vol. 183 (4) , 648-660
Open AccessNewborn screening for sickle cell disease in Europe: recommendations from a Pan‐European Consensus Conference
Summary: Sickle Cell Disease (SCD) is an increasing global health problem and presents significant challenges to European health care systems. Newborn screening (NBS) forSCDenables early initiation of preventive measures and has contributed to a reduction in childhood mortality fromSCD. Policies and methodologies forNBSvary in different countries, and this might have consequences for the quality of care and clinical outcomes forSCDacross Europe. A two‐day Pan‐European consensus conference was held in Berlin in April 2017 in order to appraise the current status ofNBSforSCDand to develop consensus‐based statements on indications and methodology forNBSforSCDin Europe. More than 50SCDexperts from 13 European countries participated in the conference. This paper aims to summarise the discussions and present consensus recommendations which can be used to support the development ofNBSprogrammes in European countries where they do not yet exist, and to review existing programmes.
- 21 September 2018
- Published by Wiley in American Journal of Hematology
- Vol. 93 (11) , 1411-1419
Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study
In order to identify very early prognostic factors that can provide insights into subsequent clinical complications, we performed a comprehensive longitudinal multi‐center cohort study on 57 infants with sickle cell anemia (55 SS; 2 Sβ°) during the first 2 years of life (ClinicalTrials.gov: NCT01207037). Time to first occurrence of a severe clinical event—acute splenic sequestration (ASS), vaso‐occlusive (VOC) event requiring hospitalization, transfusion requirement, conditional/ abnormal cerebral velocities, or death—was used as a composite endpoint. Infants were recruited at a mean age of 4.4 ±1 months. Median follow‐up was 19.4 months.During the study period, 38.6% of infants experienced ≥1 severe event: 14% ASS, 22.8% ≥ 1 VOC (median age: 13.4 and 12.8 months, respectively) and 33.3% required transfusion. Of note, 77% of the cohort was hospitalized, with febrile illness being the leading cause for admission. Univariate analysis of various biomarkers measured at enrollment showed that fetal hemoglobin (HbF) was the strongest prognostic factor of subsequent severe outcome. Other biomarkers measured at enrolment including absolute neutrophil or reticulocyte counts, expression of erythroid adhesion markers, % of dense red cells, cellular deformability or ϒ‐globin genetic variants, failed to be associated with severe clinical outcome. Multivariate analysis demonstrated that higher Hb concentration and HbF level are two independent protective factors (adjusted HRs (95% CI) 0.27 (0.11‐0.73) and 0.16 (0.06‐0.43), respectively). These findings imply that early measurement of HbF and Hb levels can identify infants at high risk for subsequent severe complications, who might maximally benefit from early disease modifying treatments.
- 21 September 2018
- Published by Wiley in American Journal of Hematology
- Vol. 93 (11) , 1411-1419
Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study
In order to identify very early prognostic factors that can provide insights into subsequent clinical complications, we performed a comprehensive longitudinal multi‐center cohort study on 57 infants with sickle cell anemia (55 SS; 2 Sβ°) during the first 2 years of life (ClinicalTrials.gov: NCT01207037). Time to first occurrence of a severe clinical event—acute splenic sequestration (ASS), vaso‐occlusive (VOC) event requiring hospitalization, transfusion requirement, conditional/ abnormal cerebral velocities, or death—was used as a composite endpoint. Infants were recruited at a mean age of 4.4 ±1 months. Median follow‐up was 19.4 months.During the study period, 38.6% of infants experienced ≥1 severe event: 14% ASS, 22.8% ≥ 1 VOC (median age: 13.4 and 12.8 months, respectively) and 33.3% required transfusion. Of note, 77% of the cohort was hospitalized, with febrile illness being the leading cause for admission. Univariate analysis of various biomarkers measured at enrollment showed that fetal hemoglobin (HbF) was the strongest prognostic factor of subsequent severe outcome. Other biomarkers measured at enrolment including absolute neutrophil or reticulocyte counts, expression of erythroid adhesion markers, % of dense red cells, cellular deformability or ϒ‐globin genetic variants, failed to be associated with severe clinical outcome. Multivariate analysis demonstrated that higher Hb concentration and HbF level are two independent protective factors (adjusted HRs (95% CI) 0.27 (0.11‐0.73) and 0.16 (0.06‐0.43), respectively). These findings imply that early measurement of HbF and Hb levels can identify infants at high risk for subsequent severe complications, who might maximally benefit from early disease modifying treatments.
- 28 August 2018
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 18 (19) , 2975-2984
A microfluidic approach to study the effect of mechanical stress on erythrocytes in sickle cell disease
This work presents a microfluidic device to challenge the deformability of normal and pathological red cells and their resistance to lysis upon mechanical stress.
- 28 August 2018
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 18 (19) , 2975-2984
A microfluidic approach to study the effect of mechanical stress on erythrocytes in sickle cell disease
This work presents a microfluidic device to challenge the deformability of normal and pathological red cells and their resistance to lysis upon mechanical stress.
- 5 February 2016
- Published by Wiley in British Journal of Haematology
- Vol. 173 (1) , 145-149
Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia
Summary: Vaso‐occlusive crisis (VOC) is the main acute complication in sickle cell anaemia (SS) and several clinical trials are investigating different drugs to improve the clinical severity of SS patients. A phase III study is currently exploring the profit of Velopoloxamer in SS during VOCs. We analysed, in‐vitro, the effect of poloxamer (P188) on red blood cell (RBC) properties by investigating haemorheology, mechanical and adhesion functions using ektacytometry, microfluidics and dynamic adhesion approaches, respectively. We show that poloxamer significantly reduces blood viscosity, RBC aggregation and adhesion to endothelial cells, supporting the beneficial use of this molecule in SS therapy.
- 5 February 2016
- Published by Wiley in British Journal of Haematology
- Vol. 173 (1) , 145-149
Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia
Summary: Vaso‐occlusive crisis (VOC) is the main acute complication in sickle cell anaemia (SS) and several clinical trials are investigating different drugs to improve the clinical severity of SS patients. A phase III study is currently exploring the profit of Velopoloxamer in SS during VOCs. We analysed, in‐vitro, the effect of poloxamer (P188) on red blood cell (RBC) properties by investigating haemorheology, mechanical and adhesion functions using ektacytometry, microfluidics and dynamic adhesion approaches, respectively. We show that poloxamer significantly reduces blood viscosity, RBC aggregation and adhesion to endothelial cells, supporting the beneficial use of this molecule in SS therapy.
- Open Access
- 24 December 2014
- Published by Elsevier in EBioMedicine
- Vol. 2 (2) , 154-157
Erythroid Adhesion Molecules in Sickle Cell Anaemia Infants: Insights Into Early Pathophysiology
- 24 December 2014
- Published by Elsevier in EBioMedicine
- Vol. 2 (2) , 154-157
Open AccessErythroid Adhesion Molecules in Sickle Cell Anaemia Infants: Insights Into Early Pathophysiology
- Open Access
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 1368
Erythroid Adhesion Molecule Expression Profile in Sickle Cell Anemia Infants
Introduction: In normal conditions, circulating red blood cells (RBCs) are not supposed to adhere. Some erythroid adhesion molecules expressed on young reticulocytes are therefore lost upon maturation. Conversely, abnormal RBC adhesiveness in sickle cell anemia (SCA) through activation, sustained or increased expression of adhesion molecules are considered central in vaso occlusive crisis (VOC), the hallmark of SCA. SCA is seldom symptomatic in the first six months of life. One main explanation lies in the sustained level of fetal hemoglobin (HbF) and F cells during this period preventing HbS polymerization. However, infra clinical vaso occlusion, particularly in the spleen, has been demonstrated to be present and the absolute reticulocyte count is paradoxically elevated in the first semester of life, evidencing the very early onset of hemolysis. Our objectives were to analyze the profile of erythroid adhesion molecules in SCA and non-SCA infants in combination with HbF level, in order to evidence significant differences specifically attributable to SCA, informative on very early pathophysiology and disease severity. Patients and methods: Infants were enrolled in a longitudinal multi center prospective study on prognostic factors in SCA between September 2010 and March 2013. Blood sampling was performed at enrolment (3-6 months) at steady state, in asymptomatic infants. In parallel, blood samples from infants with no hemoglobinopathy were collected. Flow cytometer analysis (BD FACSCanto II) was performed using murine monoclonal antibodies against CD36, CD44, CD47, CD49d, CD58, CD99, CD147, CD239 and CD242. Statistical analysis was performed with Graphpad software, Prism 6. Differences in the percentage of positive cells and the level of expression of molecules between groups were calculated with Mann Whitney test. Results were considered statistically significant at an a-risk level of 5%. Results: Fifty-four SCA infants were included and compared to 17 non-SCA infants. Median age in the two groups was not statistically different (144 days, range 81-196 versus 128, range 68-621, p=0,84). Mean HbF level was, as previously described, statistically increased in SCA compared to non-SCA infants (41.2% +/-11.2 versus 10,4 % +/- 1,8; pDiscussion: Recent publications have pointed to the significance of reticulocytosis associated with an increased risk of death or stroke during childhood. Our results further demonstrate that this early rise of reticulocyte count in SCA infants, despite elevated HbF level, include reticulocytes with a specific adhesion molecule expression profile. This numerically small subpopulation of red cells may play in fact a major role in this complex disease. An interesting hypothesis may be that the spleen, as long as its function is preserved, prevents VOC by trapping this subpopulation in very young infants. As spleen function decreases, proadhesive reticulocytes remain in the circulation, which may, in combination with the decline of HbF, subsequently favor extra splenic VOC. Ongoing analysis will confirm if this idiosyncratic erythroid adhesion molecule profile in infants indeed correlates with HbF level and, importantly, correlates with functional activation, in order to serve as a readily available biomarker of disease severity.
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 1368
Open AccessErythroid Adhesion Molecule Expression Profile in Sickle Cell Anemia Infants
Introduction: In normal conditions, circulating red blood cells (RBCs) are not supposed to adhere. Some erythroid adhesion molecules expressed on young reticulocytes are therefore lost upon maturation. Conversely, abnormal RBC adhesiveness in sickle cell anemia (SCA) through activation, sustained or increased expression of adhesion molecules are considered central in vaso occlusive crisis (VOC), the hallmark of SCA. SCA is seldom symptomatic in the first six months of life. One main explanation lies in the sustained level of fetal hemoglobin (HbF) and F cells during this period preventing HbS polymerization. However, infra clinical vaso occlusion, particularly in the spleen, has been demonstrated to be present and the absolute reticulocyte count is paradoxically elevated in the first semester of life, evidencing the very early onset of hemolysis. Our objectives were to analyze the profile of erythroid adhesion molecules in SCA and non-SCA infants in combination with HbF level, in order to evidence significant differences specifically attributable to SCA, informative on very early pathophysiology and disease severity. Patients and methods: Infants were enrolled in a longitudinal multi center prospective study on prognostic factors in SCA between September 2010 and March 2013. Blood sampling was performed at enrolment (3-6 months) at steady state, in asymptomatic infants. In parallel, blood samples from infants with no hemoglobinopathy were collected. Flow cytometer analysis (BD FACSCanto II) was performed using murine monoclonal antibodies against CD36, CD44, CD47, CD49d, CD58, CD99, CD147, CD239 and CD242. Statistical analysis was performed with Graphpad software, Prism 6. Differences in the percentage of positive cells and the level of expression of molecules between groups were calculated with Mann Whitney test. Results were considered statistically significant at an a-risk level of 5%. Results: Fifty-four SCA infants were included and compared to 17 non-SCA infants. Median age in the two groups was not statistically different (144 days, range 81-196 versus 128, range 68-621, p=0,84). Mean HbF level was, as previously described, statistically increased in SCA compared to non-SCA infants (41.2% +/-11.2 versus 10,4 % +/- 1,8; pDiscussion: Recent publications have pointed to the significance of reticulocytosis associated with an increased risk of death or stroke during childhood. Our results further demonstrate that this early rise of reticulocyte count in SCA infants, despite elevated HbF level, include reticulocytes with a specific adhesion molecule expression profile. This numerically small subpopulation of red cells may play in fact a major role in this complex disease. An interesting hypothesis may be that the spleen, as long as its function is preserved, prevents VOC by trapping this subpopulation in very young infants. As spleen function decreases, proadhesive reticulocytes remain in the circulation, which may, in combination with the decline of HbF, subsequently favor extra splenic VOC. Ongoing analysis will confirm if this idiosyncratic erythroid adhesion molecule profile in infants indeed correlates with HbF level and, importantly, correlates with functional activation, in order to serve as a readily available biomarker of disease severity.
- Open Access
- 1 April 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (16) , 11512-11521
Hydroxycarbamide Decreases Sickle Reticulocyte Adhesion to Resting Endothelium by Inhibiting Endothelial Lutheran/Basal Cell Adhesion Molecule (Lu/BCAM) through Phosphodiesterase 4A Activation
- 1 April 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (16) , 11512-11521
Open AccessHydroxycarbamide Decreases Sickle Reticulocyte Adhesion to Resting Endothelium by Inhibiting Endothelial Lutheran/Basal Cell Adhesion Molecule (Lu/BCAM) through Phosphodiesterase 4A Activation